HLA-DRB1 Antibody

Flow cytometry: 1-2ug/million cells

Optimal dilution of the antibody should be determined by the researcher.

This MAb reacts with a 28kDa chain of HLA-DRB1 antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.

Purified

0.2 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

Human REH cells (a non-T, non-B leukemia cell line) were used as the immunogen for the HLA-DRB1 antibody.

This HLA-DRB1 antibody is available for research use only.

Protein G affinity chromatography

Human

P01911